Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
Changing the FDA biosimilar interchangeability standards is a necessary but likely insufficient step to improve biosimilar ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of Accessible Medicines tackle the FDA's recent draft guidance on comparative ...
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment.
New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced treatment effectiveness and stability. People living with hidradenitis ...
FDA approves Poherdy, the first interchangeable biosimilar for pertuzumab (Perjeta), enhancing competition in HER2-positive breast cancer treatment. The FDA has granted approval to Poherdy (pertuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback